Kerecis, founded in 2010, is developing the Kerecis Omega3 fish skin graft technology for use in products to treat chronic wounds, for hernia repair, breast reconstruction and abdominal wall reconstruction. Their patented acellular fish skin material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.  The company has raised $10.8 million from private investors in Iceland, U.S., UK and France.

Follow the link to read up on some recent activities including clinical research.

Source: Under Current News

Pin It on Pinterest